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Acute pancreatitis (AP) is a severe and potentially fatal disease caused predominantly by alcohol 
excess and gallstones, which lacks a specific therapy. The role of Receptor-Interacting Protein 
Kinase 1 (RIPK1), a key component of programmed necrosis (Necroptosis), is unclear in AP. 
We assessed the effects of RIPK1 inhibitor Necrostatin-1 (Nec-1) and RIPK1 modification 
(RIPK1K45A: kinase dead) in bile acid (TLCS-AP), alcoholic (FAEE-AP) and caerulein 
hyperstimulation (CER-AP) mouse models. Involvement of collateral Nec-1 target indoleamine 
2,3-dioxygenase (IDO) was probed with the inhibitor Epacadostat (EPA). Effects of Nec-1 and 
RIPK1K45A were also compared on pancreatic acinar cell (PAC) fate in vitro and underlying 
mechanisms explored. Nec-1 markedly ameliorated histological and biochemical changes in all 
models. However, these were only partially reduced or unchanged in RIPK1K45A mice. Inhibition 
of IDO with EPA was protective in TLCS-AP. Both Nec-1 and RIPK1K45A modification inhibited 
TLCS- and FAEE-induced PAC necrosis in vitro. Nec-1 did not affect TLCS-induced Ca2+ entry 
in PACs, however, it inhibited an associated ROS elevation. The results demonstrate protective 
actions of Nec-1 in multiple models. However, RIPK1-dependent necroptosis only partially 
contributed to beneficial effects, and actions on targets such as IDO are likely to be important. 
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Acute pancreatitis (AP) is a painful, debilitating inflammatory disease with a 
significant mortality. The incidence of AP has increased in recent decades and places a 
considerable burden on health-care provision [1]. Core to the development of AP is damage to 
exocrine tissue, with extensive parenchymal necrosis that determines clinical outcome; in 
severe cases a systemic inflammatory response syndrome (SIRS), multiple organ failure and 
patient death may ensue. However, our understanding of cell death mechanisms in AP is 
incomplete and currently there is no specific therapy for the disease; identification and 
development of novel approaches is therefore paramount [2].  
Studies have demonstrated that a variety of AP precipitants including bile acids, non-
oxidative ethanol metabolites (fatty acid ethyl esters: FAEEs) and cholecystokinin 
hyperstimulation, raise cytosolic Ca2+ in the pancreatic acinar cell (PAC) in a sustained manner, 
causing opening of the mitochondrial permeability transition pore (MPTP), mitochondrial 
depolarization, rundown of ATP production and necrosis [3-5]. Necrosis is considered a largely 
uncontrolled event that results in lysis of the cell membrane, allowing escape of cellular 
contents into the interstitial compartment. Necroptosis, a programmed form of necrosis, has the 
same endpoint as necrosis but is differentiated by integral activation of receptor interacting 
protein kinase 1 (RIPK1), RIPK3 and mixed lineage kinase domain-like protein (MLKL). It 
constitutes a regulated cell death programme in response to activation of death receptors, Toll- 
and NOD-like receptors, T cell receptors, genotoxic stress and viruses [6]. RIPK1 involvement 
has been shown in necroptosis-associated disease, including myocardial infarction, stroke, 
neurodegeneration and ischaemia-reperfusion injury [7-9] 
However, relatively few studies have addressed the involvement of necroptosis in AP; 
so far these have produced mixed results, with many relying on a single experimental model. 
Genetic knockout studies have shown that RIPK3-/- mice were protected from caerulein (CER)-
AP and taurolithocholic acid sulphate (TLCS)-AP [10-12], while MLKL-/- ameliorated CER-AP 
[13]. In contrast, RIPK1KD/KD D138N and RIPK1 P-loop deficient RIP1Δ/Δ mice were not protected 
from CER-AP [12,14]. Similarly, there have been differing outcomes in studies assessing 
pharmacological inhibition of necroptosis. For example, the RIPK1 inhibitor necrostatin-1 
(Nec-1) was unprotective in CER-AP, and moreover increased pancreatic damage when 
combined with the pan-caspase inhibitor zVAD [15]. Conversely, protective effects of Nec-1 
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have been reported in CER-AP, TLCS-AP [10] and L-arginine-induced pancreatitis [16], 
although to-date no studies have examined the effects of Nec-1 and the role of necroptosis in 
alcoholic AP. Interestingly, although Nec-1 has been widely used as an inhibitor of RIPK1, it 
possesses other targets including indoleamine 2,3-dioxygenase (IDO), an enzyme involved in 
tryptophan metabolism. Recent seminal work by the Mole group has demonstrated the 
importance of the kynurenine pathway, downstream of IDO, in the development of AP both in 
patient and animal studies and is considered a promising therapeutic target [17,18]. 
Here we have evaluated the involvement of RIPK1 in AP using a RIPK1 kinase-dead 
(RIPK1K45A) mouse and pharmacological inhibition in three in vivo models reflecting the 
principal aetiologies, including our recent alcoholic AP model (FAEE-AP)[4]. These were 
combined with respective in vitro cell death assays. The results demonstrate that while Nec-1 
treatment markedly ameliorated AP in all models, RIPK1 kinase modification caused only 
partial or no protection, indicating only a minor role of RIPK1-mediated necroptosis. 
Pharmacological inhibition of IDO was protective in AP and actions of Nec-1 on collateral 
targets are likely to be important for its beneficial effects. 
 
MATERIALS AND METHODS  
Animals  
For in vivo and in vitro experiments, 8-10 weeks old male C57BL/6J mice (Charles 
River Ltd. Margate, Kent, UK) and male RIPK1K45Amice were used. RIPK1K45A mice were 
generously provided by GlaxoSmithKline [19]. Genotyping of mice was performed using 
standard PCR with a primer set (69277flp-JEM2, 5'-
CTCTGATTGCTTTATAGGACACAGCACTAAGC-3'; 69278flp-JEM2, 5'-
GTCTTCAGTGATGTCTTCCTCGTATATTTCTCAAG-3'; 473bp for the Wild-type allele, 
575bp for the RIPK1K45A allele). 
Experimental acute pancreatitis 
TLCS-AP was induced by pancreatic ductal infusion of 3 mM TLCS at 5 l/min for 
10 minutes via an infusion pump as described previously [20]; FAEE-AP was induced by 2 
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hourly intraperitoneal injections of 1.35 g/kg ethanol and 150 mg/kg palmitoleic acid 
(POA)[4],and mice sacrificed 24 hours later. CER-AP was induced by 7 hourly intraperitoneal 
cerulein injections at a dose of 50 mg/kg [3] and mice sacrificed 12 hours later. In all models, 
analgesia was administered using 0.1 mg/kg buprenorphine hydrochloride (Temgesic, Reckitt 
and Coleman, Hull, England). All experimental protocols were approved by the local ethics 
committee (University of Liverpool). Nec-1 (Sigma-Aldrich, N9073) was dissolved in 10% 
DMSO + 90% PEG 400 and administered at a dose of 56 mg/kg consistently for 12/24 hours 
via subcutaneous osmotic mini-pump (Charles River UK, Ltd, ALZET osmotic mini-pumps 
(2001D)). Epacadostat (EPA) (Selleck Chemicals, INCB24360) was dissolved in 10% DMSO 
+ 90% PEG 400 and delivered through osmotic mini pump at the dose of 50 mg/kg [21]. 
Osmotic mini-pumps for treatments (Nec-1, EPA) were inserted into the mice 0.5 h after TLCS-
AP induction, after the 2nd injection of POA in FAEE-AP and after the 3rd injection of caerulein 
in CER-AP [22].  
Histological analysis and biochemical measurements of acute pancreatitis 
Pancreatic tissue was collected and fixed in 10% formalin, embedded in paraffin and 
stained with H&E. Scoring was performed on 10 random fields by 2 blinded investigators 
independently grading edema, inflammatory cell infiltration, and acinar necrosis (scale; 0 - 3) 
as described previously [3] and data presented as the mean ± SEM (≥ 5 mice/group). Pancreatic 
trypsin activity was determined with an established protocol [22] using trypsin peptide Boc-
Gln-Ala-Arg-MCA substrate (Peptides International, Louisville, KY) with excitation at 380 nm 
and emission at 440 nm. Serum amylase was determined using a Roche Analyzer; serum 
interleukin (IL)-6 was determined by enzyme-linked immunosorbent assay (R&D Systems); 
myeloperoxidase (MPO) activity was measured according to an established protocol [22]using 
a plate reader, calculated as the difference between 0 and 3 minutes at an absorbance 
wavelength of 655 nm. Histological and biochemical responses were normalized to control 
changes after AP induction in C57BL/6J mice for each model, to compare the effects of Nec-1 
treatment or RIPK1K45Amodification across AP models. 
Cell preparation and solutions 
Freshly isolated murine PACs were obtained from the pancreas of 8-10 week-old 
C57BL/6J or RIPK1K45Amice using a standard collagenase digestion procedure [4]. The 
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extracellular solution contained (mM): 140 NaCl, 4.7 KCl, 1.13 MgCl2, 1 CaCl2, 10 D-glucose, 
and 10 HEPES. The final pH of the solution was adjusted to pH 7.35. All experiments on 
isolated PACs were performed no more than 4 h after isolation unless otherwise stated. 
Immunofluorescence  
Freshly isolated murine PACs were added to poly-L-lysine coated 35mm glass bottom 
dishes and left to adhere for 30 mins at room temperature (RT). Cells were then fixed in 4% 
paraformaldehyde for 20 mins, permeabilized with 0.2% Triton X-100 for 5 mins, blocked with 
10% goat serum and 1% bovine serum albumen in PBS for 1 hr at RT (BSA; Sigma-Aldrich, 
A3294), then incubated with primary antibodies against RIPK1 (Mouse Anti-RIP from BD 
Transduction Lab: BD610458, 1:200), RIPK3 (Rabbit Anti-RIP3 from Abcam: ab152130; 
1:100) 1 hr at RT then incubated with corresponding secondary antibody(s), Goat anti-mouse 
(H + L) lgG (Alexa Fluor 488, A-11001 Invitrogen,1:1000) and Goat anti-rabbit (H + L) lgG 
(Alexa Fluor 647, A-21244 Invitrogen, 1:500), for 30 mins at RT in the dark. Cells were 
preserved in Azide PBS prior to imaging.  
Western blotting 
Isolated PACs were unstimulated or treated with TLCS for 0 h, 2 h and 4 h at 37°C. 
Protein was extracted by radioimmunoprecipitation assay (RIPA) buffer (Sigma-Aldrich, 
R0278) containing protease inhibitor cocktail (Thermo Scientific, 87785), phosphatase cocktail 
2 (Sigma-Aldrich, P5726) and phosphatase cocktail 3 (Sigma-Aldrich, P0044) rotated for 30 
min and centrifuged at 16,000 g for 15 min at 4 °C. Protein concentration was determined by 
the BCA assay (ThermoFisher Scientific). Proteins were separated by SDS-PAGE using a 
NuPAGETM 4%-12% Bis-Tris Protein Gels (ThermoFisher scientific) and transferred onto 
nitrocellulose membranes. Non-specific binding was blocked by 3% (w/v) non-fat milk in PBS 
for 1 hour. Blots were then incubated at 4 °C overnight with primary antibody to cytochrome 
C (BD PharmingenTM: 556433, 1:500), Calnexin (Sigma, C4731, 1:1000), RIPK1 (Mouse Anti-
RIP from BD Transduction Lab: BD610458, 1:200), RIPK3 (Rabbit Anti-RIP3 from Abcam: 
ab152130; 1:200) in 3% (w/v) non-fat milk in PBS. After the first antibody, the membranes 
were washed once with 0.05%-tween in PBS and 3 times with PBS (5 min each). Then they 
were incubated for 1 h with corresponding peroxidase-labelled secondary antibody in 3% (w/v) 
non-fat milk in PBS. Blots were developed for visualization using an enhanced 
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chemiluminescence (ECL) detection kit (Thermo Scientific) through a Bio-Rad ChemiDocTM 
XRS+ System. The pixel intensities of the bands were calculated using ImageLab software. 
Measurement of necrosis and apoptosis 
Confocal imaging was performed using a Zeiss LSM710 system. Freshly isolated 
murine PACs were stimulated with either TLCS (500 M) or POAEE (100 M) at room 
temperature for 30 min with or without Nec-1 (30 µM). The total cell number was detected by 
Hoechst 33342 (10 µg/mL; excitation 364 nm, emission 405-450 nm; Molecular Probes, 
H3570) and necrosis measured by Propidium Iodide (PI) (10 g/ml; excitation 488 nm, 
emission 630-693 nm; Sigma, P4170). The total number of cells showing PI uptake in each 
group was counted from at least 12 random fields and presented as a percentage of the total cell 
number. Freshly isolated murine PACs were incubated with CellEvent® Caspase 3/7 green 
(Life Technologies, C10423) with or without Nec-1 (30 µM) for 30 mins at 37°C and then 
stimulated with TLCS (500 M) or POAEE (100 M) to induce apoptosis over an 8 h period 
(excitation filter 540 nM; emission filter 590 nM) in POLARstar Omega Plate Reader (BMG 
Labtech, Germany). 
Measurement of cytosolic calcium and reactive oxygen species  
Fluorescence imaging was performed using an Olympus IX71 based inverted imaging 
system (Till Photonics GmbH, Germany). Freshly isolated murine PACs were loaded with 
Fura2-AM (3 M; excitation at 340 and 380 nm, emission recorded with 510 nm filter) to 
measure cytosolic calcium ([Ca2+]c). The cells were attached to cover slips coated with poly-L-
lysine (0.01%) and placed in an open chamber on the microscope stage and perfused with 
extracellular solution (see above) to obtain a stable baseline (180-200s). For ROS 
measurements, PACs were loaded with 5 μM chloromethyl-2,7-dichlorodihydrofluorescein 
diacetate (CM-H2DCFDA) with and without Nec-1 for 30 mins at 37°C. Cells were placed into 
a 96 well plate-reader and ROS production measured in response to stimulation with AP toxins 
at 37°C for 5 hours (excitation 488 nm and emission 520 nm; POLARstar Omega Plate Reader; 
BMG Labtech, Germany).  
Statistical analysis  
In order to compare results from the three in vivo AP models together, responses after 
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AP induction in WT were averaged and normalization (to 100) was performed for each model: 
(intervention group/AP induction in WT）x 100. Prism 5.0 software (GraphPad Software Inc., 
La Jolla, CA) was used to perform statistical analyses, using ANOVA with Tukey post-hoc test 
or a Student T-test as appropriate. Results are presented as mean ± SEM obtained from three 




Effects of genetic and pharmacological RIPK1 inhibition in FAEE-AP, TLCS-AP and 
CER-AP 
The genotyping of RIPK1K45A homozygous mice revealed a distinct band at 575 bp 
denoting RIPK (Supplementary Figure 1a). In PACs from RIPK1K45A and WT mice there was 
a similar expression and distribution of RIPK1 and RIPK3, assessed by Western blotting and 
confocal immunofluorescence (Supplementary Figures 1b and 1c). 
Induction of AP in 3 distinct models (TLCS-AP, FAEE-AP and CER-AP) caused 
significant histopathological pancreatic damage (Figure 1a), consistent with previous studies 
[4,22]. In RIPK1K45A mice there was no significant reduction of total histopathological scores in 
either FAEE-AP or TLCS-AP compared to control WT mice, although there was partial 
protection in CER-AP (Figures 1a and 1b). In contrast, Nec-1 treatment reduced pancreatic 
damage in all experimental AP models, with significantly reduced oedema, inflammation and 
necrosis scores (Figures 1a and 1b). Similarly, Nec-1 treatment significantly improved 
biochemical parameters in all 3 AP models (Figure 2). Consistent with histological data, the 
effects of RIPK1K45A on biochemical parameters did not reflect those of pharmacological 
inhibition, with either no or partial inhibition observed in the AP models. Thus, whereas Nec-
1 reduced amylase elevations in all three models, RIPK1K45A modification caused only a partial 
reduction in FAEE-AP, with no significant effect in either TLCS-AP or CER-AP (Figure 2a). 
Both Nec-1 treatment and RIPK1K45A modification decreased elevated trypsin levels in FAEE-
AP, however, only Nec-1 treatment was protective in CER-AP (Figure 2b). Raised pancreatic 
and lung MPO levels were greatly reduced by Nec-1 treatment in all AP models. However, 
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RIPK1K45A only partially decreased the former in TLCS-AP and CER-AP, with no effect in 
FAEE-AP (Figure 2c) and was without effect on raised lung MPO levels in all models (Figure 
2d). Increases of IL-6 in FAEE-AP and TLCS-AP were significantly reduced by Nec-1 
treatment, whereas RIPK1K45A was only protective in TLCS-AP (Figure 2e) 
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Figure 1. Comparison of histological damage in FAEE-AP, TLCS-AP and CER-AP in RIPK1K45A 
and WT mice. a) Representative H&E pancreas images (x200) from sham (control), FAEE-AP, TLCS-
AP, CER-AP in RIPK1K45A, WT, and WT with Nec-1 treatment. b) Pancreatic histology scores ((i) total 
score, (ii) necrosis, (iii) inflammation and (iv) oedema) in three AP models. Each dot represents a mouse. 
Responses were normalized to control changes after AP induction in WT and are expressed as the mean 
± SEM (≥5 mice/group). Significant differences between RIPK1K45A or Nec-1 treatment groups from 




Figure 2. Comparison of biochemical changes in FAEE-AP, TLCS-AP and CER-AP in 
RIPK1K45A and WT mice. Changes in the levels of a) amylase, b) trypsin, c) pancreatic 
myeloperoxidase (MPO), d) lung MPO and e) interleukin-6 (IL-6) are shown in three AP models. Each 
dot represents a mouse. Responses were normalized to control changes after AP induction in WT and 
are expressed as the mean ± SEM (≥5 mice/group). Significant differences between RIPK1K45A or Nec-
1 treatment groups from control are shown as *p<0.05. 
 
Protective effects of IDO inhibition in TLCS-AP 
A secondary target of Nec-1, IDO, was subsequently investigated using the TLCS-AP 
model. Inhibition of IDO with Epacadostat (EPA) treatment markedly decreased local 
pancreatic damage, with significant reductions of oedema, inflammation and necrosis (Figures 
3a and 3b). In addition, EPA reduced the elevated pancreatic MPO in TLCS-AP, with a trend 
to lower serum amylase in EPA-treated compared to the non-treated group, although this did 




Figure 3. Protective effects of Epacadostat in TLCS-AP. a) Representative H&E pancreas images 
(x200) from sham (control) and TLCS-AP in WT, with and without epacadostat (EPA) treatment. 
Changes in b) pancreatic histological damage ((i) total score, (ii) necrosis, (iii) inflammation and (iv) 
oedema and biochemical alterations of (v) amylase and (vi) pancreas myeloperoxidase (MPO) in TLCS-
AP with and without EPA treatment. Each dot represents a mouse. Responses were normalized to 
control changes after AP induction in WT and are expressed as the mean ± SEM (≥5 mice/group). 




Comparative effects of RIPK1K45A and Nec-1 on PAC cell death 
In in vitro cell death assays no differences were detected in the basal levels of necrosis between 
RIPK1K45A and WT PACs or of apoptosis between RIPK1K45A and WT PACs (Figure 4). Both 
TLCS and POAEE caused necrosis that was significantly reduced by the RIPK1K45A 
modification and by Nec-1 application in WT (Figure 4a). TLCS also increased apoptotic cell 
death in RIPK1K45A and WT PACs, while POAEE was without effect. There was a significantly 
greater induction of apoptosis in response to TLCS in the RIPK1K45A mice compared to WT. 
Nec-1 significantly reduced TLCS-induced apoptosis to control levels, whereas it did not alter 
apoptosis levels in the presence of POAEE (Figure 4b). Furthermore, the appearance of 
cytosolic cytochrome C in response to TLCS was accelerated in RIPK1K45A PACs compared to 




Figure 4. Effects of RIPK1K45A and Nec-1 on TLCS- and POAEE-induced pancreatic acinar cell 
(PAC) death. a) Bar graph showing the effects of RIPK1K45A modification and Nec-1 (10 M) on 
TLCS (500 M)- and POAEE (100 M)-induced necrosis (propidium iodide (PI) uptake). Changes are 
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normalized as the ratio of total cell number to necrotic cell number. b) Bar graph showing the effects 
of RIPK1K45A modification and Nec-1 (10 M) on TLCS (500 M) and POAEE (100 M) induced 
apoptosis (Caspase-3/7 green). The data are normalized as F/F0. c) (i) Representative western blot 
images showing cytochrome C (58 KD) protein level in WT and RIPK1K45A PACs at 0, 2 and 4 h with 
or without TLCS (500 M). (ii) Bar graph showing the quantification of cytoplasm cytochrome C levels 
in WT and RIPK1K45A PACs at 0, 2 and 4 h with or without TLCS (500 M). Each dot represents a 
mouse. All data are expressed as the mean ± SEM (n≥3 mice/group). Significant differences are shown 
as * p<0.05 and # p<0.05. 
 
Comparative effects of RIPK1K45A and Nec-1 on intracellular Ca2+ and ROS 
In order to assess the possible involvement of RIPK1 in PAC [Ca2+]c overload that 
leads to necrosis [22,23], the effects of Nec-1 on TLCS-induced [Ca2+]c elevations in isolated 
PACs from WT mice were investigated. Application of TLCS (500 µM) induced a typical rapid 
peak elevation of [Ca2+]c followed by a sustained plateau. However, subsequent addition of 
Nec-1 did not inhibit the sustained Ca2+rise (Figure 5a). Furthermore, in separate experiments 
Nec-1 did not alter store-operated Ca2+ entry induced by depletion of intracellular stores with 
the SERCA pump inhibitor thapsigargin; the sustained increase of [Ca2+]c upon readmission of 
extracellular Ca2+ was unaffected by Nec-1. In contrast, addition of the Orai-1 inhibitor GSK-





Figure 5. Nec-1 does not inhibit Ca2+ entry mechanisms in PACs. a) Graph showing the effects of 
Nec-1 (30 M) on TLCS (500 M)-induced sustained cytosolic Ca2+ elevations (Fura2-AM) in PACs. 
TLCS (500 M) was applied at 200s (blue; n=97 cells) and effects of Nec-1, added at 600s, were 
compared to time-matched controls (black; n=77 cells). b) Graph showing the effects of Nec-1 (30 M) 
on store-operated Ca2+ entry (SOCE) in PACs. Thapsigargin was applied under Ca2+-free conditions to 
elicit internal store depletion. Subsequently 5 mM Ca2+ was added from 1000s to 1800s to induce 
SOCE; effects of Nec-1 applied at 1800s (blue; n=66 cells) were compared to time-matched controls 
(black; n=54 cells). The Orai1 inhibitor GSK-7975A (10 μM) was applied as a positive control at 2500s 
to reverse the SOCE. Changes are normalized increases in fluorescence from the baseline (F/F0) in b) 
and (F/F1800) in c) and data expressed as the mean ± SEM (n≥3 mice/group). Significant differences 




Since TLCS has been shown to cause Ca2+-dependent ROS generation in both human 
and murine PACs [23], the effects of RIPK1 activity on intracellular ROS were 
assessed using the RIPK1K45A modification and pharmacological inhibition (Figure 6). 
Basal ROS levels were similar in RIPK1K45A and WT PACs. Application of 500 µM 
TLCS induced a ROS elevation in WT PACs; a trend to greater TLCS-induced ROS 
was observed in RIPK1K45A PACs compared to WT, although this did not attain 
statistical significance. While Nec-1 (30 µM) did not affect basal ROS generation per 
se, it significantly decreased TLCS-induced ROS production. In contrast, application 
of POAEE (100 µM) did not increase ROS levels in either WT or RIPK1K45A PACs, 
and 30 µM Nec-1 did not alter ROS levels in the presence of POAEE (Figure 6). 
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Figure 6. Inhibitory effects of Nec-1 on intracellular ROS in PACs. Line graphs showing the effects 
of RIPK1K45A modification and Nec-1 (30 M) on intracellular ROS levels (H2DCFDA) in the presence 
of a) TLCS (500 M) and b) POAEE (100 M). c) Bar graph showing the endpoint effects of 
RIPK1K45A modification and Nec-1 on intracellular ROS levels at 5 hours in the presence of TLCS and 
POAEE. Each dot represents a mouse. Changes are normalized increases in fluorescence from the 
baseline (F/F0) and data expressed as the mean ± SEM (n≥3 mice/group; n.b. some traces have overlap 




Our results show that Nec-1 was highly effective in ameliorating pathological events 
in multiple AP models that reflect the principal aetiologies, including for the first time a 
protective action in alcoholic AP. Alcohol excess and gallstones together account for 
approximately 80% of clinical AP cases, however, no specific therapy is currently available to 
combat this debilitating and sometimes fatal disease. Previously Nec-1 has been evaluated as 
potential treatment for a range of pathologies, including ischemia-reperfusion injury [24-28], 
neurodegeneration [29,30], inflammatory disease [31,32], hepatitis [33] and lethal irradiation [34]. 
However, prior studies in AP assessing the action of Nec-1 and involvement of necroptosis 
have generated mixed findings. For example, while Nec-1 improved CER-AP, TLCS-AP [10] 
and L-arginine-induced AP [16], it was ineffective in two evaluations of CER-AP [15,35]. Such 
discrepancies may reflect differences in methodologies and/or variability in the delivery of 
Nec-1. In the present study, in order to ensure a stable and consistent Nec-1 application due to 
its relatively short half-life [36], the RIPK1 inhibitor was administered via osmotic mini-pump 
allowing an accurate comparison across three distinct AP models, as previously employed to 
investigate Orai1 inhibitors [22]. Using this standardised approach, our data demonstrate that 
Nec-1 is effective in multiple AP models when applied as a treatment i.e. after AP induction, 
strongly supporting further investigation of its actions to assist drug discovery. 
RIPK1 is one of 28 kinases implicated in AP based on an interactions network derived 
from Gene Ontology Annotations [37]. Investigation of RIPK1 involvement by complete 
knockout of the protein is not feasible since these animals die shortly after birth [38]. Our results 
demonstrate that genetic modification of RIPK1 to a kinase dead variant (RIPK1K45A) did not 
mirror those of pharmacological inhibition, and indicate only a partial involvement of RIPK1-
dependent necroptosis in AP. In accord, prior evaluations using genetic mutations showed that 
no protection was afforded by RIPK1KD/KD D138N or by RIPK1 P-loop deficient RIP1Δ/Δ mice in 
CER-AP [12,14]. In contrast, genetic deletion of RIPK3 or MLKL ameliorated both CER-AP 
and TLCS-AP [10-13]. Interestingly, evidence suggests that both RIPK1 and RIPK3 may not 
always be prerequisites for necroptosis to occur [39]. For example, TLR3-induced necroptosis 
in fibroblasts and endothelial cells did not require RIPK1 but involved both RIPK3 and MLKL 
[40], whilst necroptosis due to cytomegalovirus infection was RIPK1-independent but involved 
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RIPK3 activity [41]. More recently, pancreatic tumour-promoting effects of RIPK1 were shown 
to be independent of its co-association with RIPK3 [42]. 
While recent evidence supports an involvement of necroptosis in the pathogenesis of 
AP, the contribution of RIPK1 appears variable and dependent on aetiology. Here the extent of 
RIPK1-dependent necroptosis differed according to the AP model, with pancreatic injury in 
RIPK1K45A mice significantly reduced compared to WT in CER-AP. This contrasted with little 
or no protection observed in TLCS-AP and FAEE-AP, implying a more extensive participation 
of RIPK1 in CER-AP. In isolated PACs, the involvement of RIPK1 in cell death modalities 
was complex; whilst TLCS-induced PAC necrosis was reduced by the RIPK1K45A modification, 
apoptosis was potentiated. The latter was linked to earlier release of cytochrome C from 
mitochondria in RIPK1K45A mice, accompanied by ROS elevation, consistent with previous 
studies demonstrating ROS driven apoptosis in this cell type [23,43]. Previously deletion of X-
linked inhibitor of apoptosis protein was shown to increase both RIPK1 degradation and 
caspase activity, resulting in enhanced PAC apoptosis and reduced necrosis that ameliorated 
AP [44]. Our findings of increased TLCS-induced apoptosis, with concurrent reduction of 
necrosis in RIPK1K45A mice, are consistent with an alteration of the apoptosis-necrosis balance 
that influences AP severity [23,45-47]. 
 In contrast to genetic manipulation, Nec-1 application reduced both apoptotic and 
necrotic PAC death, indicating multiple actions that determine responses to pathophysiological 
stimulation. Previously, TLCS-induced necrosome formation, ATP depletion and cell death in 
PACs were reduced by Ca2+ chelation with BAPTA pre-treatment [10]. In the present study 
Nec-1 did not alter the sustained [Ca2+]c elevations caused by TLCS in PACs, implying 
protective actions distal to Ca2+ release and store-operated Ca2+entry mechanisms engaged by 
bile acids [48,49]. Interestingly, the Ca2+-dependent ROS elevations induced by TLCS [23] were 
reduced by Nec-1, consistent with reported inhibitory actions on acetaminophen-induced ROS 
production and mitochondrial dysfunction in hepatocytes [50], and TNFα-induced ROS 
accumulation and cell death in NF-κB activation-deficient cells [51]. The ability of Nec-1 to 
decrease TLCS-induced ROS is likely to be of importance to its beneficial actions in AP. A 
recent study has demonstrated a role of transient receptor potential melastatin 2 (TRPM2) 




The effects of Nec-1 application in disease studies have largely been attributed to 
RIPK1 inhibition. Our present findings strongly indicate that multiple mechanisms contribute 
to its protective effects in AP; to-date no investigations have addressed the possible 
involvement of collateral targets of Nec-1 in AP. Amongst those inhibited by Nec-1 is IDO, 
the initial, rate-limiting component of the kynurenine pathway involved in cellular tryptophan 
metabolism, known to have a complex role in inflammation and disease [53,54]. Early studies 
showed that inhibition of IDO could increase the severity of diseases, including asthma [55], 
uveoretinitis [56] and colitis [57]. However, investigations have also demonstrated that IDO1 
deficiency/inhibition reduced inflammation and metaplasia in chronic gastric inflammation 
[58], the development of allergic airway disease [59], and ameliorated rheumatoid arthritis 
symptoms via a diminished autoreactive B cell response [60]. In the present study, treatment 
with EPA, a highly selective and potent IDO1 inhibitor [61], was protective against pancreatic 
damage in TLCS-AP, indicating that actions on this enzyme likely contribute to beneficial 
effects of Nec-1. Although the expression of IDO was not evaluated here, upregulation of both 
IDO1 and IDO2 have been shown in human pancreatic ductal adenocarcinoma [62,63] and a 
more detailed evaluation of IDO involvement in AP is the focus of a separate, on-going study. 
The present findings are consistent with recent studies which have demonstrated the importance 
of the kynurenine pathway to AP. Increased plasma levels of 3-hydroxykynurenine in AP 
patients paralleled disease severity in clinical AP [64], while inhibition of kynurenine-3-
monooxygenase, an enzyme downstream of IDO, prevented multiple organ failure in rodent 
AP models [18]; a series of kynurenine-3-monooxygenase inhibitors is now in development for 
AP therapy [17]. Interestingly, it has also been shown that Nec-1 exerts cyclophilin D-dependent 
beneficial actions in cardiac ischaemia-reperfusion injury [65]. A collateral inhibitory effect of 
Nec-1 on cyclophilin D would also be advantageous in AP, since genetic deletion (ppif-/-) and 
pharmacological inhibition of this protein prevented mitochondrial permeability transition pore 
(MPTP) formation in the exocrine pancreas and protected against AP [3,66-69]. Thus, multiple 
actions of Nec-1 provide an aggregation of complementary beneficial effects of potential 
therapeutic value in AP and serve as a starting point for development of novel agents. 
In conclusion, our study has demonstrated important protective actions of Nec-1 in 
multiple AP models, including for the first time in alcoholic AP. However, RIPK1 kinase 
modification only partially reflected the effects of Nec-1. The efficacy of Nec-1 treatment 
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indicates that inhibition of multiple targets might be an effective therapeutic strategy in AP and 
further investigation is warranted. 
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Supplementary Figure 1. Expression and distribution of RIPK1 and RIPK3 in RIPK1K45A and strain-
matched WT PACs. a) PCR experiments distinguished WT, heterozygous and homozygous RIPK1K45A mice. 
Each lane represents a single mouse (575 bp: RIPK1K45A homozygous; 473 bp: WT and both 575 bp and 473 bp: 
RIPK1K45A heterozygous). b) Representative western blotting images of RIPK1 (60 KD) and RIPK3 (57 KD) in 
WT and RIPK1K45A PACs. Calnexin (92 KD) was used as a loading control. c) Immunofluorescence images of 
RIPK1 (green) and RIPK3 (magenta) showing distribution in isolated PACs from WT and RIPK1K45A (scale bar: 
10 μm). All data are representative of at least 3 experiments. 
